Week in Review: Charles River Labs Buys China’s Vital River

Charles River Labs will pay $27 million to acquire a 75% stake in Vital River, the largest supplier of laboratory animals in China; Fosun Pharma posted a loss in its first day of trading in Hong Kong; DelMar Pharma of Canada and Guangxi Wuzhou Pharma will expand their collaboration by seeking approval of new indications of Wuzhou’s cancer drug in China; Hutchison MediPharma began a Phase I clinical trial of Theliatinib in patients with lung cancer; a new generic GI drug from Sihuan Pharma received SFDA approval; SLG-Giant Pharm Service Group, a China clinical-stage CRO, will conduct the China arm of a hypertension trial for the NIH of the US; Innovent Biologics of Suzhou, which intends to in-license biologic drugs and provide CMO services, is building a biotech manufacturing facility in BioBay; and Xiamen Innovax Biotech has launched Hecolin, the world's first hepatitis E vaccine, in the China market. More details…. Stock Symbols: (NYSE: CRL) (SHA: 600196; HK: 2196) (AIM: HCM) (HK: 0460) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});